Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3366 participants
OBSERVATIONAL
2022-07-15
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In addition to the main effect of replacing lost blood, red blood cell concentrates also have many undesirable effects - from blood group compatibilities, which are easily avoidable due to care, to storage-related side effects, to mostly intensive care problems as a result of massive transfusions, to system-wide effects such as TRALI, TACO and TRIM.
Before being administered to patients, red blood cell concentrates undergo an extensive quality assurance process in which a large number of parameters are collected. Prior to use on patients, for example, bedside tests and tests for further incompatibilities with a blood sample from the intended patient are performed. With the implementation of Patient Blood Management (PBM) in recent years, the use of red cell concentrates has become more targeted - the number of transfusions is decreasing in most developed countries. However, it is still possible to suffer transfusion-related adverse events (TRAE). Thus, active research activity to reduce these TRAEs continues to be called for.
To date, however, it is not known which patients experience transfusion-related adverse events. Despite the broad measures of hemovigilance and pre-transfusion testing, it is still not possible to predict which individual patient will respond to a transfusion with a typical adverse event such as hypotension, hemolysis, renal failure, or TRALI. It seems understandable that characteristics of the patient as well as characteristics of the administered unit could play a role for this. In particular, it is conceivable that a combination of characteristics of the blood unit and characteristics of the patient could determine a complication in the course of administration. For this reason, it seems attractive to use artificial intelligence and machine learning methods to predict any complications.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery
NCT04856618
Blood Storage Related Mortality and Adverse Effects in Trauma Patients
NCT07341139
Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)
NCT02280655
Early Whole Blood in Patients Requiring Transfusion After Major Trauma
NCT01227005
Australian and New Zealand Massive Transfusion Registry
NCT02863250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AKI
Acute Kidney Injury
Transfusion of Allogeneic Blood
Transfusion of Allogeneic Blood
ARF
Acute Respiratory Failure
Transfusion of Allogeneic Blood
Transfusion of Allogeneic Blood
AKI and ARF
Acute Kidney Injury and Acute Respiratory Failure
Transfusion of Allogeneic Blood
Transfusion of Allogeneic Blood
no complication
no complication
Transfusion of Allogeneic Blood
Transfusion of Allogeneic Blood
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transfusion of Allogeneic Blood
Transfusion of Allogeneic Blood
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kepler University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Tschoellitsch, MD
Role: PRINCIPAL_INVESTIGATOR
Kepler University Hospital and Johannes Kepler University, Linz, Austria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kepler University Hospital
Linz, Upper Austria, Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tschoellitsch T, Moser P, Maletzky A, Seidl P, Bock C, Roland T, Ludwig H, Sussner S, Hochreiter S, Meier J. Potential Predictors for Deterioration of Renal Function After Transfusion. Anesth Analg. 2024 Mar 1;138(3):645-654. doi: 10.1213/ANE.0000000000006720. Epub 2024 Feb 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRETRACO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.